Inhibitory Effect of the HASPIN Inhibitor CHR-6494 on BxPC-3-Luc, A Luciferase-Expressing Pancreatic Cancer Cell Line

HASPIN acts in chromosome segregation via histone phosphorylation. Recently, HASPIN inhibitors have been shown to suppress growth of various cancer cells. Pancreatic cancer has no symptom in the early stages and may progress before detection. So, the 5-year survival rate is low. Here, we reported th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Hiromitsu, Nishida-Fukuda, Hisayo, Wada, Morimasa, Tokuhiro, Keizo, Matsushita, Hiroaki, Ando, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royan Institute 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124445/
https://www.ncbi.nlm.nih.gov/pubmed/35674022
http://dx.doi.org/10.22074/cellj.2022.7796
Descripción
Sumario:HASPIN acts in chromosome segregation via histone phosphorylation. Recently, HASPIN inhibitors have been shown to suppress growth of various cancer cells. Pancreatic cancer has no symptom in the early stages and may progress before detection. So, the 5-year survival rate is low. Here, we reported that administration of the HASPIN inhibitor, CHR-6494, to mice bearing pancreatic BxPC-3-Luc cancer cells significantly suppressed growth of BxPC-3-Luc cells. CHR-6494 might be a useful agent for treating pancreatic cancer.

Ejemplares similares